SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Aurora Cannabis Inc (OTCMKTS:ACBFF) reported that it has engaged Cam Battley as company’s Executive Vice President. In his new role, Battley, who previously served as Senior VP, Communications and Medical Affairs, will look after the company’s corporate development and organizational effectiveness, along with the current responsibilities pertaining to business development, and patient, medical and other stakeholder measures, communications and investor relations.

Mr. Battley, who has extensive global experience in the biotech and pharmaceutical division, currently is one of the members of Cannabis Canada’s board, the trade association for legal producers of medical cannabis. He serves as Chairman of the Advocacy Committee. Prior to joining Aurora, he was VP, Communications and Corporate Development for a leading Licensed Producer.

Terry Booth, the CEO, said that Battley appointment will help drive company’s leadership, growth and innovation, and further improve their status across multiple functions. His passion, knowledge and experience will continue to make them a better organization.

The performance

In last week of October, Aurora released its operational and financial results for the quarter ended June 30, 2016. For the quarter closed June 30, 2016, the firm posted revenues of $1.2 million as compared to $0 for the same period in the preceding year. The company received its sales and production licenses during the year and began offering medical cannabis products in January 2016.  Revenues recorded to date highlight what management thinks is the fastest growth pace of active registered patients in the market as the firm moves to full production capacity.

Aurora has established itself as an innovator and leader in the cannabis industry. Since beginning commercial businesses earlier in January, they have witnessed rapid revenue growth, recorded a notable patient registration rate, generated substantial capital for the execution of strategic and operational initiatives, and considerably enhanced balance sheet, with an impressive cash position in the sector.

The CEO said that they have enhanced and expanded board and management team with highly accomplished experts, offering more breadth and depth, as well as strengthening corporate governance. In preparation for the remarkable growth they expect in this market and for firm, they reported plans to enhance production capacity to nearly 70,000 kilograms annually through the construction of automated greenhouse facility that shows the state-of-the-art agricultural technology.